Moderator | Number of study estimates | Β | 95% CI | p value | R 2 |
---|---|---|---|---|---|
Progressive aerobic training | |||||
Mean age | 14 | 0.045 | − 0.074; 0.166 | 0.457 | 0.00 |
Percentage of women in the sample | 10 | − 0.007 | − 0.056; 0.041 | 0.765 | 0.00 |
Body mass index | 13 | − 0.737 | − 1.346; − 0.128 | 0.017 | 0.20 |
Diagnosis duration | 11 | 0.076 | −0.069; 0.223 | 0.303 | 0.00 |
Baseline HbA1c | 10 | 0.009 | −1.508; 1.318 | 0.895 | 0.00 |
Glucose lowering drug users | 5 | − 0.080 | − 0.113; − 0.046 | < 0.001 | 1.00 |
Follow-up duration | 14 | − 0.088 | − 0.147; − 0.029 | 0.003 | 0.37 |
Weekly frequency | 14 | − 0.426 | − 1.677; 0.825 | 0.504 | 0.00 |
Session duration | 13 | − 0.005 | − 0.055; 0.043 | 0.820 | 0.00 |
Weekly duration | 13 | 0.001 | − 0.016; 0.017 | 0.960 | 0.00 |
Non-progressive aerobic training | |||||
Mean age | 12 | 0.001 | − 0.001; 0.002 | 0.442 | 0.00 |
Percentage of women in the sample | 10 | 0.003 | − 0.013; 0.021 | 0.662 | 0.00 |
Body mass índex | 12 | 0.096 | − 0.039; 0.232 | 0.163 | 0.00 |
Diagnosis duration | 10 | − 0.015 | − 0.449; 0.417 | 0.942 | 0.00 |
Baseline HbA1c | 12 | − 0.229 | − 0.898; 0.440 | 0.502 | 0.06 |
Glucose lowering drug users | 8 | − 0.027 | − 0.099; 0.045 | 0.462 | 0.00 |
Follow-up duration | 13 | 0.005 | − 0.046; 0.056 | 0.846 | 0.00 |
Session duration | 13 | − 0.026 | − 0.058; 0.007 | 0.128 | 0.09 |
Weekly frequency | 13 | − 0.536 | − 0.904; − 0.168 | 0.004 | 0.38 |
Weekly duration | 13 | − 0.005 | − 0.010; − 0.001 | 0.020 | 0.27 |